Shattuck Labs, Inc. (NASDAQ:STTK) Shares Purchased by Deutsche Bank AG

Deutsche Bank AG boosted its stake in shares of Shattuck Labs, Inc. (NASDAQ:STTK) by 476.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 116,868 shares of the company’s stock after buying an additional 96,594 shares during the period. Deutsche Bank AG owned 0.24% of Shattuck Labs worth $141,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in STTK. Virtu Financial LLC acquired a new position in Shattuck Labs during the fourth quarter worth $30,000. JPMorgan Chase & Co. boosted its stake in Shattuck Labs by 382.0% during the fourth quarter. JPMorgan Chase & Co. now owns 132,696 shares of the company’s stock worth $161,000 after buying an additional 105,163 shares during the last quarter. Takeda Pharmaceutical Co. Ltd. acquired a new position in Shattuck Labs during the fourth quarter worth $624,000. Zacks Investment Management acquired a new position in Shattuck Labs during the fourth quarter worth $25,000. Finally, Adage Capital Partners GP L.L.C. boosted its stake in Shattuck Labs by 61.2% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 4,675,000 shares of the company’s stock worth $5,657,000 after buying an additional 1,775,000 shares during the last quarter. Institutional investors and hedge funds own 58.74% of the company’s stock.

Shattuck Labs Stock Down 2.4%

Shares of Shattuck Labs stock opened at $1.02 on Wednesday. Shattuck Labs, Inc. has a 52 week low of $0.69 and a 52 week high of $7.49. The business’s fifty day simple moving average is $0.95 and its 200-day simple moving average is $1.12. The firm has a market cap of $48.86 million, a PE ratio of -0.67 and a beta of 1.74.

Shattuck Labs (NASDAQ:STTK) last announced its quarterly earnings results on Thursday, May 1st. The company reported ($0.27) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.02. Shattuck Labs had a negative return on equity of 61.92% and a negative net margin of 1,156.46%. As a group, equities analysts expect that Shattuck Labs, Inc. will post -1.48 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. Leerink Partnrs raised Shattuck Labs to a “strong-buy” rating in a research note on Monday, March 17th. HC Wainwright reaffirmed a “neutral” rating on shares of Shattuck Labs in a research note on Thursday, March 27th. Needham & Company LLC reaffirmed a “hold” rating on shares of Shattuck Labs in a research note on Thursday, March 27th. Finally, Leerink Partners assumed coverage on Shattuck Labs in a research note on Monday, March 17th. They issued an “outperform” rating and a $4.00 price target on the stock. Four research analysts have rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, Shattuck Labs presently has a consensus rating of “Moderate Buy” and an average target price of $7.50.

Shattuck Labs Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.